What is enGene Holdings Inc Annual Net Profit?

enGene Holdings Inc Annual Net Profit rose 44.81% in the last year to $55.14 M. Its sector's average net profit growth for the last fiscal year was 18.23%.

What is enGene Holdings Inc Price to Earning Ratio?

enGene Holdings Inc Price to Earning Ratio is -3.44, which is negative.

What is enGene Holdings Inc Stock Price?

enGene Holdings Inc Stock Price fell 74.08% and underperformed its sector by 100.45% in the past year.

What is enGene Holdings Inc Quarterly Net profit?

enGene Holdings Inc Quarterly Net profit fell 129.82% YoY to $24.62 M. Its sector's average net profit growth YoY for the quarter was 36.27%.

What is enGene Holdings Inc Debt to Equity Ratio?

enGene Holdings Inc Debt to Equity Ratio of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is enGene Holdings Inc Return on Equity(ROE)?

enGene Holdings Inc Return on Equity(ROE) for the last financial year was -31.96%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is enGene Holdings Inc Mutual Fund Holding?

enGene Holdings Inc Mutual Fund Holding increased by 0.01% in the last quarter to 3.3.

What is enGene Holdings Inc Interest Coverage Ratio?

enGene Holdings Inc Interest Coverage Ratio is -18.71, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

What is enGene Holdings Inc Institutional Holding?

enGene Holdings Inc Institutional Holding increased by 15.5% in the last quarter to 83.04.

How is the enGene Holdings Inc today?

The enGene Holdings Inc today is trading in the down by -1.06% at 4.66.

How has enGene Holdings Inc performed historically?

The enGene Holdings Inc is currently trading down -1.06% on an intraday basis in the past week the index fell -11.74%. The index has been down -28.20% in the past quarter and fell -74.08% in the past year. You can view this in the overview section.

enGene Holdings Inc XNAS: ENGN

enGene Holdings Inc Live Share Price Today, Share Analysis and Chart

Name: enGene Holdings Inc: Is Infosys Ltd. worth buying?
Item: enGene Holdings Inc
Rating: 0.97891675
Author: Trendlyne DVM scores

Download real time

4.66 -0.05 (-1.06%)

New 52W Low today

99 XNAS Volume

XNAS 25 Mar, 2025 5:30 PM (EDT)

enGene Holdings Inc Key Metrics

My Metrics

Default

Market Capitalization Below industry Median Unavailable in chosen country	237.6
PE TTM Negative PE TTM Unavailable in chosen country	-3.4
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.1
Price to Book Below industry Median Unavailable in chosen country	0.9
Institutional holding current Qtr % High in industry Unavailable in chosen country	83
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-129.8
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	33.1
Piotroski Score Below industry Median Unavailable in chosen country	2
Rel Perf vs Sector quarter% Unavailable in chosen country	-34.6
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-32
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-27.7

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

13.2 / 100

Technically Bearish

26.0 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

enGene Holdings Inc Stock Price Analysis

Day Price Range -1.1% 1 Day return Unavailable in chosen country	4.7 (LTP) 44.7 LowHigh
Week Price Range -11.7% 1 Week return Unavailable in chosen country	4.7 (LTP) 45.5 LowHigh
Month Price Range -19.9% 1 Month return Unavailable in chosen country	4.7 (LTP) 46.4 LowHigh
52 Week Price Range -74.1% 1 Year return Unavailable in chosen country	4.7 (LTP) 418.4 LowHigh

View full Share Price History

enGene Holdings Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

enGene Holdings Inc Stock Analysis

enGene Holdings Inc stock analysis with key metrics, changes, and trends.

enGene Holdings Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$55.14 M	44.81%	positive	Annual Net Profit rose 44.81% in the last year to $55.14 M. Its sector's average net profit growth for the last fiscal year was 18.23%.
Price to Earning Ratio	-3.44	-	negative	Price to Earning Ratio is -3.44, which is negative.
Stock Price	$4.66	-74.08%	negative	Stock Price fell 74.08% and underperformed its sector by 100.45% in the past year.
Quarterly Net profit	$24.62 M	129.82%	negative	Quarterly Net profit fell 129.82% YoY to $24.62 M. Its sector's average net profit growth YoY for the quarter was 36.27%.
Debt to Equity Ratio	0.09	-	positive	Debt to Equity Ratio of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-31.96 %	-31.96%	negative	Return on Equity(ROE) for the last financial year was -31.96%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	3.30 %	0.01%	positive	Mutual Fund Holding increased by 0.01% in the last quarter to 3.3.
Interest Coverage Ratio	-18.71	-	negative	Interest Coverage Ratio is -18.71, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).
Institutional Holding	83.04 %	15.5%	positive	Institutional Holding increased by 15.5% in the last quarter to 83.04.

VIEW LESS

Loading data..

enGene Holdings Inc - Company Profile

What does enGene Holdings Inc do?

enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Gross Remuneration

2024

Gross Remuneration

Year

enGene Holdings Inc Live Share Price Today, Share Analysis and Chart

New 52W Low today

enGene Holdings Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

enGene Holdings Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

enGene Holdings Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

enGene Holdings Inc Stock Analysis

enGene Holdings Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 44.81% in the last year to $55.14 M. Its sector's average net profit growth for the last fiscal year was 18.23%.

Price to Earning Ratio is -3.44, which is negative.

Stock Price fell 74.08% and underperformed its sector by 100.45% in the past year.

Quarterly Net profit fell 129.82% YoY to $24.62 M. Its sector's average net profit growth YoY for the quarter was 36.27%.

Debt to Equity Ratio of 0.09 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -31.96%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding increased by 0.01% in the last quarter to 3.3.

Interest Coverage Ratio is -18.71, lesser than one. This means that it is unable to pay interests with its earnings (EBIT).

Institutional Holding increased by 15.5% in the last quarter to 83.04.

enGene Holdings Inc - Company Profile

What does enGene Holdings Inc do?

enGene Holdings Inc Management structure

Dr. Richard P. Bryce

Chief Medical Officer of the Company and enGene USA, Inc.

Mr. Ryan Daws

Chief Financial Officer, Head of Business Development and Principal Accounting Officer

Mr. Alexandre Jean-Rene Erwan Grassin

Interim Chief Financial Officer

Mr. Jason D. Hanson, B.S.,J.D.

Director; Chief Executive Officer of Company and enGene Inc

Mr. Ronald H.W. Cooper

President, Chief Executive Officer and Director

Dr. Raj Som Pruthi, M.D.

Chief Medical Officer

enGene Holdings Inc Board of directors

Mr. Jason D. Hanson, B.S.,J.D.

Director; Chief Executive Officer of Company and e

Ms. Lota S. Zoth, C.P.A.

Director

Mr. Paul J. Hastings

Independent Director

Mr. Wouter Joustra

Independent Director

Mr. Ronald H.W. Cooper

President, Chief Executive Officer and Director

Dr. Richard M. Glickman,L.L.D.

Independent Director; Chairman of the Board of enG

enGene Holdings Inc FAQ

How is enGene Holdings Inc today?

enGene Holdings Inc today is trading in the red, and is down by -1.06% at 4.66.

How has enGene Holdings Inc performed historically?

enGene Holdings Inc is currently trading down -1.06% on an intraday basis. In the past week the stock fell -11.74%. stock has been down -28.20% in the past quarter and fell -74.08% in the past year. You can view this in the overview section.